Literature DB >> 15165541

Restless legs syndrome in end-stage renal disease.

Gian Luigi Gigli1, Massimo Adorati, Pierluigi Dolso, Antonella Piani, Mariarosaria Valente, Stefania Brotini, Riccardo Budai.   

Abstract

BACKGROUND AND
PURPOSE: Patients undergoing dialysis therapy due to end-stage renal disease (ESRD) present a high prevalence of sleep disorders, including restless legs syndrome (RLS). However, the known data generally have been obtained from relatively small patient samples, coming from single or very few dialysis units. Moreover, some data were collected prior to the recent improvements in dialysis techniques, pharmacological therapies and to the establishment of internationally recognised diagnostic criteria for RLS. PATIENTS AND METHODS: In order to study the incidence of the different sleep disorders, and of RLS in particular, in a large population of dialysis patients, a questionnaire was administered to all the patients in dialysis units of the 'Triveneto' area (Italy) who agreed to participate. The first part of the questionnaire included questions about demographic data, general medical history, history of renal disease, dialytic treatment and pharmacological therapy. The second part, which was self-administered, explored the patient's complaints about sleep, the presence of the minimal International Restless Legs Syndrome Study Group (IRLSSG) criteria for the diagnosis of RLS, the Epworth Sleepiness Scale and questions particularly related to somnolence. Patients whose responses indicated a diagnosis of RLS according to the IRLSSG criteria were requested to answer the 10 questions of the IRLSSG Severity Scale. The same group of patients was compared to those who did not fulfil any of the four minimal criteria for RLS. Statistical analysis was performed by using ANOVA and non-parametric tests. Whenever possible, data were compared with the database of the Veneto Dialysis Register. The first 601 consecutive questionnaires that we were able to analyse are presented in this paper.
RESULTS: Applying the IRLSSG criteria for the diagnosis, the percentage of RLS patients in our sample was 21.5%, with a score of 20.5+/-8.7 on the IRLSSG Severity Scale. Comparing patients who are definitely affected by RLS (n=127) with unaffected patients (n=280), we found that the two groups did not differ as to age, sex, weight, body mass index (BMI), and intake of nicotine, alcohol and caffeine. Similarly, the two groups did not differ as to the etiology of ESRD, type of dialysis or percentage of previous transplantations; however, the period of dialysis dependence was significantly lower in the group negative for RLS. The use of drugs did not differ in the two groups, except for lower intake of phosphorus binders and antihypertensive drugs among RLS patients. No patient was receiving specific treatment for RLS. RLS patients reported more fragmented, less restful nightly sleep and more daytime somnolence, more often presented symptoms of other sleep disorders and were more affected by anxiety or depression.
CONCLUSIONS: The high prevalence of RLS and other sleep disorders among uremics requires careful investigation of nocturnal sleep; although often underdiagnosed, correct identification of these disorders can lead to better therapy and improvement of clinical conditions and quality of life. Sleep fragmentation and sleep deprivation caused by RLS may contribute to the cardiovascular complications and infections, often with bad prognosis in dialysis patients.

Entities:  

Mesh:

Year:  2004        PMID: 15165541     DOI: 10.1016/j.sleep.2004.01.014

Source DB:  PubMed          Journal:  Sleep Med        ISSN: 1389-9457            Impact factor:   3.492


  52 in total

Review 1.  Restless legs syndrome: a comprehensive overview on its epidemiology, risk factors, and treatment.

Authors:  Paul Yeh; Arthur S Walters; John W Tsuang
Journal:  Sleep Breath       Date:  2011-10-26       Impact factor: 2.816

2.  Restless legs syndrome in dialysis patients: a comparison between hemodialysis and continuous ambulatory peritoneal dialysis.

Authors:  Giovanni Merlino; Simone Lorenzut; Giulio Romano; Martina Sommaro; Augusto Fontana; Domenico Montanaro; Mariarosaria Valente; Gian Luigi Gigli
Journal:  Neurol Sci       Date:  2012-01-22       Impact factor: 3.307

Review 3.  Management of restless legs syndrome in patients on dialysis.

Authors:  Miklos Z Molnar; Marta Novak; Istvan Mucsi
Journal:  Drugs       Date:  2006       Impact factor: 9.546

4.  Prevalence and polysomnographic correlates of insomnia comorbid with medical disorders.

Authors:  Rohit Budhiraja; Thomas Roth; David W Hudgel; Pooja Budhiraja; Christopher L Drake
Journal:  Sleep       Date:  2011-07-01       Impact factor: 5.849

5.  Restless legs syndrome in hemodialysis patients: association with depression and quality of life.

Authors:  Deniz Tuncel; Fatma Ozlem Orhan; Hayriye Sayarlioglu; Ismet Onder Isık; Uygar Utku; Aytac Dinc
Journal:  Sleep Breath       Date:  2010-07-01       Impact factor: 2.816

6.  Racial differences in restless legs symptoms and serum ferritin in an incident dialysis patient cohort.

Authors:  Nancy G Kutner; Rebecca Zhang; Yijian Huang; Donald L Bliwise
Journal:  Int Urol Nephrol       Date:  2012-01-05       Impact factor: 2.370

Review 7.  Sleep disorders and quality of life in renal transplant recipients.

Authors:  Miklos Zsolt Molnar; Marta Novak; Istvan Mucsi
Journal:  Int Urol Nephrol       Date:  2009-01-31       Impact factor: 2.370

8.  The high prevalence of restless legs syndrome symptoms in liver disease in an academic-based hepatology practice.

Authors:  Rose A Franco; Ramesh Ashwathnarayan; Arshana Deshpandee; Joshua Knox; Jack Daniel; Daniel Eastwood; Jose Franco; Kia Saeian
Journal:  J Clin Sleep Med       Date:  2008-02-15       Impact factor: 4.062

Review 9.  Treatment of restless legs syndrome.

Authors:  Cynthia L Comella
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

10.  Restless legs syndrome in systemic lupus erythematosus: A case-control study.

Authors:  Cristian Falup-Pecurariu; Anca Enache; Liliana Duca; Camil Fotescu; Oana Falup-Pecurariu; Vlad Monescu; Ştefania Diaconu; Carmen Adella Sirbu
Journal:  Exp Ther Med       Date:  2021-05-26       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.